Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2020 1
2021 2
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %
The following terms were not found in PubMed: 5BAuth
Page 1
UK Medical Cannabis Registry palliative care patients cohort: initial experience and outcomes.
Nimalan D, Kawka M, Erridge S, Ergisi M, Harris M, Salazar O, Ali R, Loupasaki K, Holvey C, Coomber R, Platt M, Rucker JJ, Khan S, Sodergren MH. Nimalan D, et al. Among authors: ali r. J Cannabis Res. 2022 Jan 4;4(1):3. doi: 10.1186/s42238-021-00114-9. J Cannabis Res. 2022. PMID: 34980282 Free PMC article.
The primary outcome consisted of changes in patient-reported outcome measures including EQ-5D-5L, General Anxiety Disorder-7 (GAD-7), Single-Item Sleep Quality Scale (SQS), Pain Visual Analog Scale (VAS) and the Australia-Modified Karnofsky Performance Scale at 1 and 3 mon …
The primary outcome consisted of changes in patient-reported outcome measures including EQ-5D-5L, General Anxiety Disorder-7 (GAD-7), …
UK Medical Cannabis registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions.
Harris M, Erridge S, Ergisi M, Nimalan D, Kawka M, Salazar O, Ali R, Loupasaki K, Holvey C, Coomber R, Usmani A, Sajad M, Hoare J, Rucker JJ, Platt M, Sodergren MH. Harris M, et al. Among authors: ali r. Expert Rev Clin Pharmacol. 2022 Apr;15(4):473-485. doi: 10.1080/17512433.2022.2017771. Epub 2021 Dec 31. Expert Rev Clin Pharmacol. 2022. PMID: 34937477
Primary outcomes were changes in Brief Pain Inventory short-form (BPI), Short-form McGill Pain Questionnaire-2 (SF-MPQ-2), Visual Analogue Scale-Pain (VAS), General Anxiety Disorder-7 (GAD-7), Sleep Quality Scale (SQS), and EQ-5D-5L, at 1, 3, and 6 months from baseline. St …
Primary outcomes were changes in Brief Pain Inventory short-form (BPI), Short-form McGill Pain Questionnaire-2 (SF-MPQ-2), Visual Analogue S …
An Updated Analysis of Clinical Outcome Measures Across Patients From the UK Medical Cannabis Registry.
Ergisi M, Erridge S, Harris M, Kawka M, Nimalan D, Salazar O, Loupasaki K, Ali R, Holvey C, Coomber R, Usmani A, Sajad M, Beri S, Hoare J, Khan SA, Weatherall MW, Platt M, Rucker JJ, Sodergren MH. Ergisi M, et al. Among authors: ali r. Cannabis Cannabinoid Res. 2023 Jun;8(3):557-566. doi: 10.1089/can.2021.0145. Epub 2022 Jan 24. Cannabis Cannabinoid Res. 2023. PMID: 35073160
Primary outcomes included change from baseline in patient-reported outcome measures collected across all patients (the Generalized Anxiety Disorder Scale [GAD-7], EQ-5D-5L, and Sleep Quality Scale [SQS]) at 1, 3, and 6 months. Secondary outcomes included the self-reported …
Primary outcomes included change from baseline in patient-reported outcome measures collected across all patients (the Generalized Anxiety D …
UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for generalized anxiety disorder.
Ergisi M, Erridge S, Harris M, Kawka M, Nimalan D, Salazar O, Loupasaki K, Ali R, Holvey C, Coomber R, Platt M, Rucker JJ, Sodergren MH. Ergisi M, et al. Among authors: ali r. Expert Rev Clin Pharmacol. 2022 Apr;15(4):487-495. doi: 10.1080/17512433.2022.2020640. Epub 2022 Jan 18. Expert Rev Clin Pharmacol. 2022. PMID: 34937473
Primary outcomes included changes from baseline in patient-reported outcome measures (the General Anxiety Disorder Scale (GAD-7), EQ-5D-5L (a measure of health-related quality of life), and Sleep Quality Scale (SQS)) at 1, 3 and 6 months. ...Statistically significant impro …
Primary outcomes included changes from baseline in patient-reported outcome measures (the General Anxiety Disorder Scale (GAD-7), EQ-5D …
Quality of life as a predictor of time to heroin relapse among male residents following release from compulsory rehabilitation centres in Vietnam.
Vuong T, Ritter A, Shanahan M, Ali R, Nguyen N, Minh KP. Vuong T, et al. Among authors: ali r. Drug Alcohol Rev. 2021 Feb;40(2):296-306. doi: 10.1111/dar.13176. Epub 2020 Sep 28. Drug Alcohol Rev. 2021. PMID: 32985029

While the total index score (across the five pre-specified EQ-5D domains) did not have a significant effect in predicting cumulative relapse, lower scores on the Visual Analogue Scale of the EQ-5D were significantly (P < 0.05) predictive of cumulative relapse, wi

…
While the total index score (across the five pre-specified EQ-5D domains) did not have a significant effect in predicting cumulative …
Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31].
Al-Chalabi A, Shaw PJ, Young CA, Morrison KE, Murphy C, Thornhill M, Kelly J, Steen IN, Leigh PN; UKMND-LiCALS. Al-Chalabi A, et al. BMC Neurol. 2011 Sep 21;11:111. doi: 10.1186/1471-2377-11-111. BMC Neurol. 2011. PMID: 21936930 Free PMC article. Clinical Trial.
Secondary outcome measures will be changes in three functional rating scales, the ALS Functional Rating Scale-Revised, The EuroQOL (EQ-5D), and the Hospital Anxiety and Depression Scale.Eligible patients will have El Escorial Possible, Laboratory-supported Probable, Probab …
Secondary outcome measures will be changes in three functional rating scales, the ALS Functional Rating Scale-Revised, The EuroQOL (EQ-5D …